Navigation Links
Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Date:9/11/2008

EMERYVILLE, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its fiscal 2008 fourth quarter and year-end financial results on September 16, 2008.

The Company will also host a call to discuss its financial results. Details for the fiscal year-end call are as follows:

-- Date: Tuesday, September 16, 2008

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 877-874-1565 U.S. & Canada / 719-325-4822 International

The web cast can be accessed online at: http://investor.shareholder.com/ntii/events.cfm

Telephonic Replay: A playback of the conference call will be available from 1:30 pm (ET) on September 16, 2008 to midnight (ET) on September 23, 2008. Reply number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 2312764

The presentation at the Merriman Curhan Ford Investor Summit will take place on Monday, September 15, 2008 at 10:15 a.m. at the Mark Hopkins InterContinental Hotel in San Francisco. Access to the presentation can be found at: http://investor.shareholder.com/ntii/events.cfm

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies CEO to Retire on December 31, 2008
3. Neurobiological Technologies Reports Third Quarter Financial Results
4. Neurobiological Technologies Sets Date for Third Quarter Financial Results
5. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
6. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
7. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
8. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
9. Neurobiological Technologies Sets Date for Research and Development Day
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
11. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Crucial Life Sciences Data ... 4.1, greatly improves performance of the platform. In particular, Version 4.1 boosts performance ... of data to be collected on a per patient basis. Clinical Studio has ...
(Date:5/5/2016)... Irvine, CA (PRWEB) , ... May 05, 2016 ... ... has closed on a definitive agreement to acquire Algynomics, a research-stage pain diagnostics ... prospective data to identify individuals at increased risk for the development of chronic ...
(Date:5/5/2016)... , May 5, 2016  Why are two uber-successful ... Lorna Weir launching a new venture—yet going ... they believe that truly helping clients raise the value ... now demands a different type of collaboration. ... the pharmaceutical, biotechnology and medical device sectors. Elevate specializes ...
(Date:5/4/2016)... ... May 05, 2016 , ... CereScan, the nation’s leader ... Association during National Stroke Awareness Month in May. An infographic created by ... month. CereScan will donate $1 up to a maximum of $3,000 through ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
(Date:3/10/2016)... -- --> --> ... Access Management Market by Component (Provisioning, Directory Services, Password ... Size, by Deployment, by Vertical, and by Region - ... is estimated to grow from USD 7.20 Billion in ... Compound Annual Growth Rate (CAGR) of 12.2% during the ...
(Date:3/9/2016)... 2016 Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> Nigeria ... more than 23,000 public service employees either did not ... their salary unlawfully.    --> DERMALOG, the ...
Breaking Biology News(10 mins):